WallStreetZenWallStreetZen

NASDAQ: NBIX
Neurocrine Biosciences Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

NBIX past earnings growth

How has NBIX's earnings growth performed historically?
Company
59.01%
Industry
13.17%
Market
62.15%
NBIX's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
NBIX's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Market Performance
NBIX's earnings growth is slowing... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

NBIX past revenue growth

How has NBIX's revenue growth performed historically?
Company
26.76%
Industry
10.21%
Market
17.33%
NBIX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
NBIX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
NBIX's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

NBIX earnings and revenue history

Current Revenue
$1.9B
Current Earnings
$249.7M
Current Profit Margin
13.2%

NBIX Return on Equity

Current Company
12.9%
Current Industry
15.4%
Current Market
188%
NBIX's Return on Equity (12.9%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when NBIX announces earnings.

NBIX Return on Assets

Current Company
9%
Current Industry
3.4%
NBIX is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

NBIX Return on Capital Employed

Current Company
12.97%
Current Industry
5.1%
NBIX has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

NBIX vs Pharmaceutical Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
NBIX$1.89B$358.00M$249.70M+33.13%+61.92%
VTRS$15.43B$3.52B$54.70M+6.17%-40.84%
TEVA$15.85B$1.64B-$559.00M-2.81%N/A
RDY$2.99B$904.61M$547.73M+6.52%N/A
CTLT$4.10B-$754.00M-$1.30B+10.50%N/A
View Top Pharmaceutical Stocks

NBIX earnings dates

Next earnings date
May 1, 2024

Neurocrine Biosciences Earnings & Revenue FAQ

What were NBIX's earnings last quarter?

On Invalid Date, Neurocrine Biosciences (NASDAQ: NBIX) reported Q4 2023 earnings per share (EPS) of $1.51, up 64.13% year over year. Total Neurocrine Biosciences earnings for the quarter were $147.70 million. In the same quarter last year, Neurocrine Biosciences's earnings per share (EPS) was $0.92.

If you're new to stock investing, here's how to buy Neurocrine Biosciences stock.

What was NBIX's earnings growth in the past year?

As of Q2 2024, Neurocrine Biosciences's earnings has grown 59.01% year over year. This is 45.84 percentage points higher than the US Drug Manufacturers - Specialty & Generic industry earnings growth rate of 13.17%. Neurocrine Biosciences's earnings in the past year totalled $249.70 million.

What is NBIX's earnings date?

Neurocrine Biosciences's earnings date is Invalid Date. Add NBIX to your watchlist to be reminded of NBIX's next earnings announcement.

What was NBIX's revenue last quarter?

On Invalid Date, Neurocrine Biosciences (NASDAQ: NBIX) reported Q4 2023 revenue of $515.20 million up 25.05% year over year. In the same quarter last year, Neurocrine Biosciences's revenue was $412.00 million.

What was NBIX's revenue growth in the past year?

As of Q2 2024, Neurocrine Biosciences's revenue has grown 26.76% year over year. This is 16.56 percentage points higher than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 10.21%. Neurocrine Biosciences's revenue in the past year totalled $1.89 billion.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.